PANCREATIC CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Larotrectinib News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Precision Cancer Medicine, treatment


View more articles like this
More news and in-depth Pancreatic Cancer information

CONDITIONS OF THE GI TRACT